Studying Drug Resistance From a New Angle
The development of “targeted therapies” which block the function of mutant proteins within tumor cells has revolutionized the treatment landscape for many cancers, most of all lung
The development of “targeted therapies” which block the function of mutant proteins within tumor cells has revolutionized the treatment landscape for many cancers, most of all lung
Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the
In recent years, biomarker testing has grown increasingly more important and more complex as researchers understand critical details about the molecular basis of lung cancer. By
Some people with lung cancer have reduced lung function from their cancer or their treatments, like surgery, radiation, or chemotherapy. People with diminished lung functional
Checkpoint inhibitor immunotherapy has revolutionized lung cancer treatment and ushered in a new era of scientific discovery that is focused on empowering our natural immune system
Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers, and is found most often in people with a history of tobacco exposure. SCLC is an aggressive disease with
Coming to terms with a lung cancer diagnosis can be difficult. You might feel anxious, angry, or out of control. You might have difficulty sleeping or perhaps unable to even talk
53 days after Julie Jones had video assisted thoracic surgery (VATS) to remove the lower lobe of her right lung, Julie ran a half marathon. Even more impressive, she finished only
On May 28, 2021, the global lung cancer community celebrated news that the US Food & Drug Administration (FDA) has granted accelerated approval for sotarasib as a second-line
According to the National Cancer Institute, approximately 70% of lung cancer patients are initially diagnosed with advanced-stage disease, which is more difficult to treat than
Approximately 23% of non-small cell lung cancer (NSCLC) have an EGFR-positive mutation. Advanced-stage NSCLC patients whose tumors have an EGFR mutation are often treated with one